In a 60-year-old adult with a persistent cough that has not improved despite taking benzonatate 200 mg capsules, what are the possible causes and recommended treatment options with appropriate dosages?

Resistant Cough Not Responding to Benzonatate: Causes and Treatment

In a 60-year-old adult with persistent cough unresponsive to benzonatate 200mg, you should discontinue benzonatate (as it has failed and lacks robust efficacy evidence) and initiate a systematic diagnostic protocol to identify the underlying cause—most commonly postnasal drip syndrome, asthma, or gastroesophageal reflux disease—followed by targeted therapy based on findings.

Why Benzonatate Has Failed

Benzonatate is FDA-approved only for symptomatic cough relief 1, acting peripherally by anesthetizing stretch receptors in the respiratory tract 1. The maximum dose is 600mg daily in three divided doses 1, so your patient is already at 200mg TID (600mg/day maximum). However, recent systematic reviews reveal that benzonatate's approval was based on extremely limited evidence that would not meet current regulatory standards 2. The drug has minimal proven efficacy beyond very small, poorly designed studies 2.

Systematic Approach to Diagnosis

Since the cough has persisted despite benzonatate, this qualifies as chronic cough (>8 weeks duration based on typical presentation) 3. You must now follow a guideline-based diagnostic protocol:

Initial Evaluation Must Include:

1. Chest X-ray - to exclude masses, interstitial lung disease, or bronchiectasis 4
2. Spirometry with bronchodilator reversibility - to detect asthma or COPD 3, 4
3. Medication review - specifically check if patient takes ACE inhibitors (trial discontinuation if present) 4
4. Targeted history for:
   • Postnasal drip symptoms (nasal discharge, throat clearing, sensation of drainage)
   • Asthma features (wheezing, dyspnea, nocturnal symptoms)
   • GERD symptoms (heartburn, regurgitation, worse when lying down)

Most Common Causes in Adults

Research consistently shows chronic cough is caused by 5, 6:

• Postnasal drip syndrome (PND): 56% of cases
• Chronic bronchitis: 18% of cases
• Asthma/cough-variant asthma: 14% of cases
• Gastroesophageal reflux disease (GERD): 5-6% of cases
• Multiple simultaneous causes: Common (6-7% have combined PND+GERD or asthma+GERD)

Treatment Algorithm Based on Findings

If Spirometry Shows Bronchial Hyperresponsiveness or Asthma:

• Inhaled corticosteroids (ICS) - standard asthma dosing
• Trial for 4-8 weeks 7
• Add bronchodilators as needed

If Clinical Features Suggest Postnasal Drip:

• Intranasal corticosteroids (e.g., fluticasone 2 sprays each nostril daily)
• First-generation antihistamines (e.g., diphenhydramine 25-50mg at bedtime or chlorpheniramine 4mg TID)
• Decongestants if appropriate (pseudoephedrine 60mg TID, avoid if hypertensive)
• Trial for 2-4 weeks 7

If GERD Suspected Clinically:

Important caveat: The 2016 CHEST guideline specifically recommends against proton pump inhibitors in unexplained chronic cough with negative GERD workup 3. However, if clinical features strongly suggest GERD:

• Proton pump inhibitor (e.g., omeprazole 20-40mg twice daily before meals)
• Lifestyle modifications (elevate head of bed, avoid late meals)
• Trial for 8-12 weeks (GERD-related cough takes longer to respond)

If Postinfectious Cough (Recent URI within 3-8 weeks):

• Ipratropium inhaler 2 puffs QID - first-line 7
• If persistent: Inhaled corticosteroids trial 7
• For severe paroxysms: Prednisone 30-40mg daily for short course (5-7 days) 7

If Initial Trials Fail: Unexplained Chronic Cough

When cough persists after appropriate trials (typically 8+ weeks of targeted therapy), this becomes unexplained chronic cough (UCC) 3:

Recommended Treatments for UCC:

1. Speech Pathology/Cough Suppression Therapy - Grade 2C recommendation 3

   • Multimodality approach including breathing exercises, cough suppression techniques
   • Most evidence-based non-pharmacologic option

2. Gabapentin - Grade 2C recommendation 3

   • Dosing schedule: Start 300mg once daily, increase by 300mg every 1-3 days as tolerated
   • Target dose: Up to 1800mg daily in two divided doses (900mg BID)
   • Maximum: Some patients require up to 1800mg/day
   • Important: Discuss side effects (dizziness, sedation, peripheral edema) and risk-benefit profile before starting
   • Reassess risk-benefit at 6 months before continuing 3

3. Low-dose opioids (codeine, morphine) - for refractory cases 7, 8

   • Use cautiously due to side effects and dependence risk
   • Recent case reports suggest low-dose sublingual buprenorphine may be effective with better safety profile 9

What NOT to Do in UCC:

• Do NOT prescribe inhaled corticosteroids if bronchial hyperresponsiveness testing and eosinophil markers (sputum eosinophils, exhaled nitric oxide) are negative 3
• Do NOT prescribe proton pump inhibitors if GERD workup is negative 3

Common Pitfalls to Avoid

1. Assuming single cause: 6-7% of patients have multiple simultaneous causes 5. If partial response to one therapy, consider adding treatment for another potential cause.

2. Inadequate trial duration: GERD-related cough requires 8-12 weeks of therapy; don't abandon treatment prematurely.

3. Missing ACE inhibitor-induced cough: Always check medications first—this is easily reversible 4.

4. Jumping to "unexplained" diagnosis too quickly: Ensure proper trials of common causes before labeling as UCC. Success rates of 91% are achievable with systematic protocols 5.

5. Continuing benzonatate indefinitely: Since it has failed at appropriate dosing and lacks strong efficacy data 2, discontinue it and pursue diagnostic evaluation rather than empirically increasing or continuing ineffective therapy.